Koninklijke Philips (NYSE:PHG) Upgraded to “Neutral” at UBS Group

UBS Group upgraded shares of Koninklijke Philips (NYSE:PHG) from a sell rating to a neutral rating in a research note published on Tuesday, MarketBeat reports.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. upgraded shares of Koninklijke Philips from an underweight rating to a neutral rating in a research note on Tuesday. StockNews.com upgraded shares of Koninklijke Philips from a buy rating to a strong-buy rating in a research note on Thursday, February 8th. Finally, BNP Paribas downgraded shares of Koninklijke Philips from an outperform rating to an underperform rating in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $19.00.

Koninklijke Philips Price Performance

Shares of PHG opened at $26.55 on Tuesday. The company has a 50 day moving average price of $20.69 and a 200-day moving average price of $21.05. Koninklijke Philips has a fifty-two week low of $17.75 and a fifty-two week high of $29.44. The stock has a market capitalization of $24.66 billion, a PE ratio of -46.58, a PEG ratio of 1.09 and a beta of 0.88. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20.

Koninklijke Philips (NYSE:PHG) last announced its earnings results on Monday, January 29th. The technology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.47 billion. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. Equities analysts predict that Koninklijke Philips will post 1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Capital Analysts LLC increased its holdings in Koninklijke Philips by 6.3% in the fourth quarter. Capital Analysts LLC now owns 8,820 shares of the technology company’s stock valued at $206,000 after buying an additional 521 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its holdings in Koninklijke Philips by 5.7% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,374 shares of the technology company’s stock valued at $265,000 after buying an additional 615 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its holdings in Koninklijke Philips by 3.2% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 22,616 shares of the technology company’s stock valued at $451,000 after buying an additional 696 shares in the last quarter. Kovitz Investment Group Partners LLC increased its holdings in Koninklijke Philips by 1.7% in the third quarter. Kovitz Investment Group Partners LLC now owns 44,746 shares of the technology company’s stock valued at $892,000 after buying an additional 750 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in Koninklijke Philips by 34.4% in the first quarter. Fifth Third Bancorp now owns 3,008 shares of the technology company’s stock valued at $60,000 after buying an additional 770 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.